3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Melanoma
3
Lymphoma, T-Cell, Cutaneous
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
21
Cyclophosphamide
18
fludarabine
8
Radiotherapy
8
Radiosurgery
7
Nivolumab
7
poly ICLC
6
fludarabine phosphate
6
aldesleukin
6
Therapeutics
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
6
durvalumab
5
Psychiatric Rehabilitation
5
Interleukin-2
5
Drug Therapy
5
Docetaxel
5
Cisplatin
5
temsirolimus
4
cemiplimab
4
Trastuzumab
4
Temozolomide
4
Sirolimus
4
Gemcitabine
4
Flow Cytometry
4
Filgrastim
4
Carboplatin
4
tremelimumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
3
pazopanib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Interleukin-15
×
Dermatologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled